ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
11 announcements with these filters
Epigral reported 15% revenue growth and 25% EBITDA margins despite Red Sea logistical disruptions. Management is pivoting toward high-value downstream specialty chemicals like Epoxy resins to reduce commodity exposure.
Epigral Ltd will invest ₹650 Crore to add 1,25,000 TPA of Epoxy Resin & Formulations capacity at its Dahej facility, expected by H2 FY2028.
Epigral reported 15% YoY revenue growth and 25% PAT growth for Q1FY27. Strategy focuses on diversifying into high-value derivatives and specialty chemicals with significant capex for Epoxy Resin and Multi-Purpose plants.
Epigral reported Q1FY27 PAT of ₹99 Crore, a 25% YoY increase. The company plans ₹600 Crore capex for Epoxy Resin and Multi-Purpose Plant.
Epigral Limited plans to establish a new manufacturing facility for Epoxy Resin and Multi-Purpose Plant at Dahej, Gujarat. The project requires an investment of ₹600 Crore.
Epigral Ltd reported revenue from operations of ₹705.4 Cr (+16.3% YoY) and net profit of ₹99.7 Cr (-38.0% YoY) for Q1 FY27.
Epigral Ltd scheduled a board meeting for July 27, 2026. The board will consider the company's first quarter unaudited financial results.
Epigral Limited clarified that recent volume and price movements are due to market conditions. The company confirms no undisclosed price-sensitive information exists.
Epigral Ltd filed its quarterly shareholding pattern for the period ended June 30, 2026. The report details the distribution of shareholdings among various investor categories.
CRISIL reaffirmed Epigral Limited's long-term rating at AA/Stable and short-term rating at A1+. The ratings cover bank loan facilities worth Rs. 1050 Crore.
Epigral Limited incorporated a wholly-owned subsidiary, Epigral Advanced Materials Limited, for chemical manufacturing. The subsidiary has a paid-up capital of Rs. 1 lakh.